TABLE 2.

Clinical trials of TH-302.

Ref	Tumor type	Clinical trial	Number of patients	Combined therapy
Weiss et al. (2011a)	Solid tumors	Phase 1	57	—
Ganjoo et al. (2011)	Soft tissue sarcoma	Phase 1	16	Doxorubicin (chemotherapy)
Weiss et al. (2011b)	Melanoma	Phase 1	1	—
Chawla et al. (2014)	Soft tissue sarcoma	Phase 2	91	Doxorubicin (chemotherapy)
Borad et al. (2015)	Pancreatic cancer	Phase 2	214	Gemcitabine (chemotherapy)
Van Cutsem et al. (2016)	Pancreatic cancer	Phase 3	660	Gemcitabine (chemotherapy)
Badar et al. (2016)	Leukemia	Phase 1	49	—
Riedel et al. (2017)	Advanced solid tumors	Phase 1	30	Pazopanib (anti-angiogenic agents)
Conroy et al. (2017)	Ovarian serous carcinoma	Case report	2	—
Tap et al. (2017)	Soft-tissue sarcoma	Phase 3	640	Doxorubicin (chemotherapy)
Brenner et al. (2018)	Glioblastoma	Phase 1	28	Bevacizumab (anti-angiogenic agents)
Jamieson et al. (2018)	HNSCC	Phase 2	5	—
Laubach et al. (2019)	Multiple myeloma	Phase 1/2	59	Bortezomib (chemotherapy)